<DOC>
	<DOCNO>NCT02970084</DOCNO>
	<brief_summary>Clinical study single center , prospective , randomize , control ( vs. supplement ) , open-label , blind assessor ( doctor perform Doppler ultrasound 6 12 month know treatment give patient , diagnostic test question consider operator-dependent ) , `` parallel group '' , aim evaluate reduction level calcium carotid artery carotid atherosclerotic plaque , sample 60 subject present subcritical calcified lesion carotid bifurcation range 40-60 % .</brief_summary>
	<brief_title>Vitamin K2 Reduction Calcium Carotid Bifurcation Patients With Subcritical Lesions</brief_title>
	<detailed_description />
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<mesh_term>Vitamin MK 7</mesh_term>
	<criteria>1 . Age â‰¥ 18 year 2 . Ability provide write informed consent 3. subject calcified lesion subcritical carotid bifurcation . range 4060 % calculate method ECTS ( European Carotid Surgery Trial ) 1 . Patients reduce life expectancy age &gt; 80 year , 2 . Patients already subject clinical trial previous three month , 3 . Patients hypersensitivity know allergy acetylsalicylic acid , patient preexist mastocytosis , history asthma induce salicylate , duodenal ulcer , bleed diathesis , severe hepatic insufficiency , severe heart failure , concomitant treatment methotrexate , last trimester pregnancy . 4 . Patients know hypersensitivity vitamin K2 vitamin D , people hemolytic disease , concomitant anticoagulant therapy , people cancer , MAV ( arteriovenous malformation ) / cerebral aneurysm , hypercalcemia , nephrolithiasis renal failure . 5 . Uncooperative patient , allergy relate substance study contraindicate data sheet / Summary Product Characteristics ( SPC ) substances studio .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>